Breaking the cycle
of chronic pain

Neuropathic pain isn’t just discomfort—it’s
a life-altering condition affecting millions.

450 to 650 million

people affected by neuropathic pain.

US$900 bi
per year

Direct and indirect economic burden of neuropathic pain across USA and Europe.

No cure, limited solutions

Existing treatments are mainly symptomatic, with side effects
and limited long-term efficacy.

There is an urgent need for new
treatment alternatives to improve the
quality of life of millions of patients.

And we are pioneering a
breakthrough solution to transform
the way neuropathic pain is treated
—offering patients real relief where existing treatments fall short.

Who are
we?

Apateya is a startup originating from leading academic institutions in France and Canada with a highly qualified team behind the discovery and development of the AP Series.

Pascal Fossat, PhD

Professor, Team Leader@ IMN CSO, KOL chronic neuropathic pain, Co-founder and co-inventor

+ More informations

Franck Aby, PhD

Chief Executive Officer,
Co-founder and
co-inventor.

+ More informations

Hanna Zieger, PhD

Head of preclinical R&D

+ More informations

Cynthia Abboud, PhD

Head of clinical R&D

+ More informations

Aude Retailleau, PhD

Head of in vivo R&D

+ More informations

Science

How neuropathic pain works – and our path to treating it.

1 How pain is controlled

Result: Effective pain control and inhibition.

2 When pain becomes chronic

Result: Uncontrolled pain signals lead to chronic pain.

Injury or disease can damage peripheral nerves, disrupting descending pain control.

The brain fails to inhibit pain signals, leading to increased sensitivity (hyperalgesia).

Result: Uncontrolled pain signals lead to chronic pain.

3 Apateya’s breakthrough solution

AP restores dysfunctional descending
pathways, allowing proper pain inhibition.

This reduces excessive pain signaling
from the spinal cord.

Result: Pain control is restored, effectively reducing excessive transmission and alleviating chronic pain.

Apateya's AP Series

The compound AP represents a revolutionary breakthrough in the treatment of neuropathic pain. Its innovative mechanism of action restores the inhibitory processes of descending pain modulation, normalizing nociceptive transduction and perception.

Due to its proven superiority, it has the potential to quickly become the new standard in the treatment of neuropathic pain, significantly benefiting over 7% of patients with neuropathic pain and 20% of those suffering from chronic pain globally.

“AP represents a new era in the treatment of neuropathic pain”

Dr. Frédéric Villega, Neurologist

receive scientific information

Where do we stand?

Further investments will enable accelerating the next phases of clinical testing and regulatory approval of this drug that could revolutionize the entire market.

2021 — 2022